At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,278 enrolled
Drug / intervention
Pregabalindrug
Likely dose
Pregabalin 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pregabalin (Lyrica) Action In Neuropathic Pain Syndrome (PAINS): A Post Marketing Surveillance Study On Efficacy, Safety And Tolerability Of Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted May 1, 2009·Updated Jan 25, 2021
In Brief
An observational study evaluating Pregabalin for Neuropathic Pain. Completed, enrolled 2,278 participants.
Detailed Summary
This study is being conducted as a regulatory requirement post initial marketing authorization. This is primarily a safety study. This was an open label study and patients were enrolled once the decision to prescribe the medication was made by the Investigator.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
Primary CompletionAug 2008
First PostedMay 2009
TodayJul 2026
First PostedMay 1, 2009
Enrollment StartSep 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.2 years ago
Interventions
Pregabalindrug
Pregabalin 75-150 mg BID for at least 2 weeks.